CDH1

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Retrieved on: 
Sunday, June 4, 2023

(Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).

Key Points: 
  • (Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).
  • No mutations were significantly associated with response or resistance to alisertib plus paclitaxel, including those in PIK3CA, TP53, AKT1, HER2, and CDH1.
  • Increased MYC RNA expression was not observed in patients who did not appear to benefit from alisertib plus paclitaxel.
  • This biomarker analysis will be very helpful to the design of the future trials of alisertib that we are planning in hormone receptor positive HER2-negative breast cancer.”

Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression

Retrieved on: 
Monday, October 24, 2022

BEVERLY, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, TellDx, and treatment through its complementary therapeutics platform, TellRx, announces publication of data from the scientific founders that show a beneficial impact of a novel antibody targeting multiple cadherins on tumor cell dissemination in mouse models of breast and pancreatic cancer. The results were published on October 18, 2022, in Proceedings of the National Academy of Sciences (DOI 10.1073/pnas.2209563119).

Key Points: 
  • Greater than 10 million patients die from cancer each year and more than 90% of the deaths are attributed to metastasis.
  • As such, targeting CTCs with novel therapeutics could likely have a significant impact on cancer metastases and patient outcome.
  • Tumor metastasis is a multi-step process whereby cancer cells invade blood vessels through a complex process referred to epithelial-mesenchymal transition (EMT).
  • Administration of 23C6 demonstrated 100-fold reduction in CTC count in pancreatic cancer model and led to significant metastatic suppression.

Global Rare NRG1 Fusion Market Report to 2032 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022

The "Rare NRG1 Fusion - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare NRG1 Fusion - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Rare NRG1 Fusion, historical and forecasted epidemiology as well as the Rare NRG1 Fusion market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Rare NRG1 Fusion market report provides current treatment practices, emerging drugs, Rare NRG1 Fusion market share of the individual therapies, current and forecasted Rare NRG1 Fusion market size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers the current Rare NRG1 Fusion treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Debbie's Dream Foundation: Curing Stomach Cancer Hosts Virtual Stomach Cancer Educational Symposium

Retrieved on: 
Tuesday, February 1, 2022

PLANTATION, Fla., Feb. 1, 2022 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) will host its Virtual Stomach Cancer Educational Symposium on Wednesday, February 9, 2022, from 9:00 a.m. to 5:00 p.m. EST.

Key Points: 
  • PLANTATION, Fla., Feb. 1, 2022 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) will host its Virtual Stomach Cancer Educational Symposium on Wednesday, February 9, 2022, from 9:00 a.m. to 5:00 p.m. EST.
  • In addition, a two-part panel discussion will feature stomach cancer survivors, caregivers, and family members sharing their journey with the disease.
  • His expertise includes sporadic and inherited forms of stomach cancer, including CDH1 gene mutations, as well as molecular underpinnings of gastric cancer development and metastasis.
  • Stomach cancer care and impactful research require partnership, and I am thankful for Debbie's Dream Foundation for bringing together both patients and experts in the field of stomach cancer."

Tempus Announces Six Abstracts Accepted For Poster Presentation at the 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 7, 2021

Tempus , a leader in artificial intelligence and precision medicine, today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10.

Key Points: 
  • Tempus , a leader in artificial intelligence and precision medicine, today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10.
  • The presented findings highlight the unique insights that Tempus data and smart diagnostics generate to advance breast cancer research.
  • Three abstracts selected for poster presentation at SABCS 2021 are highlighted below:
    Overview: This study characterizes the genomic and transcriptomic landscape of advanced or metastatic ILC and co-mutational landscape of CDH1-mutant disease.
  • Researchers retrospectively analyzed a de-identified cohort of 4,296 patients with breast cancer who underwent Tempus xT testing.

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021

The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.

Key Points: 
  • The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
  • "This is among the most prominent scientific gatherings addressing drug discovery and molecular targets.
  • Overall, our presentations describe our IMTAC platform technology and its capabilities, the discovery of novel small-molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small-molecule drugs."
  • BridGene used the IMTAC platform to screen its unique covalent library against live-cell proteomes and discovered small-molecule ligands for WDR5.

Grant Awarded to Better Define Gastric Cancer Risks of the Hereditary Diffuse Gastric Cancer Gene CTNNA1

Retrieved on: 
Wednesday, September 29, 2021

Dr. Katona is a physician-scientist who seeks to better define the gastric cancer risks associated with the CTNNA1 gene in order to aid both patients and medical professionals in their abilities to manage the cancer risks associated with the gene.

Key Points: 
  • Dr. Katona is a physician-scientist who seeks to better define the gastric cancer risks associated with the CTNNA1 gene in order to aid both patients and medical professionals in their abilities to manage the cancer risks associated with the gene.
  • Hereditary diffuse gastric cancer syndrome (HDGC), the most common cause of familial diffuse gastric cancer, leads to substantially increased gastric cancer risk that often necessitates the prophylactic removal of the stomach for cancer prevention.The CDH1 gene was the first gene found to be associated with HDGC and remains the most common and best characterized gene associated with this condition.More recently, the CTNNA1 gene has also been shown to be associated with HDGC; however, given limitations in the amount of available data, the true gastric cancer risk for carriers of an abnormal CTNNA1 gene remain uncertain.
  • With support from the DeGregorio Family Foundation Grant Award, Dr. Katona's lab plans to conduct an international study to allow collection of cancer information from families who carry a CTNNA1 gene variant, which will allow him and his team to calculate the cancer risks associated with this gene.
  • Secondly, they will utilize gastric organoids, which are novel three-dimensional models of gastric tissue that are derived directly from biopsies of the stomach, to study how different changes in the CTNNA1 gene may contribute to gastric cancer growth.

Biocare Medical Launches 7 Novel IVD Antibodies for Clinical Diagnostic and Cancer Research Applications with a Focus on Immuno-Oncology

Retrieved on: 
Thursday, February 20, 2020

E-cadherin - A decreased expression of E-cadherin is associated with metastatic potential and poor prognosis in breast cancer, prostate, and esophageal cancer.

Key Points: 
  • E-cadherin - A decreased expression of E-cadherin is associated with metastatic potential and poor prognosis in breast cancer, prostate, and esophageal cancer.
  • "We are proud to be able to launch novel, IVD IHC markers that meet the highest standards in cancer diagnostics.
  • This commitment to quality ensures Biocare is providing the best diagnostic and research utility possible," said Dr. Jason Ramos, Vice President Reagent Research and Development at Biocare Medical.
  • The new product launches continue Biocare Medical's long-standing history of providing novel, high-quality reagents to customers looking to advance their research and diagnostic efficiency in the laboratory.

In JAMA Oncology Publication, GeneDx Describes Lower Lifetime Risk of Gastric Cancer Conferred by CDH1

Retrieved on: 
Tuesday, August 6, 2019

Germline pathogenic variants in CDH1 cause Hereditary Diffuse Gastric Cancer syndrome and result in increased risk for both diffuse gastric and lobular breast cancers.

Key Points: 
  • Germline pathogenic variants in CDH1 cause Hereditary Diffuse Gastric Cancer syndrome and result in increased risk for both diffuse gastric and lobular breast cancers.
  • Previous studies assessing CDH1associated cancer risks were research based and mostly in families with strong histories of gastric cancer, often three or more gastric cancers in the family, which lead to overestimation of gastric cancer risks.
  • In this study, GeneDx and the University of Washington estimated CDH1-associated cancer risks based on a group of patients that were not selected based on strong family histories of gastric cancer.
  • The estimates derived in the JAMA Oncology paper suggest that lifetime gastric cancer risk is lower than previously reported, albeit still substantially elevated for such an overall deadly cancer, says Jeremy Davis, surgeon-scientist in the National Cancer Institutes Center for Cancer Research.